| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/28/2023 | 501.5% | Truist Securities | → $12 | Reiterates | Buy → Buy |
| 11/17/2023 | 451.38% | Baird | → $11 | Initiates Coverage On | → Outperform |
| 11/08/2023 | — | Maxim Group | Downgrades | Buy → Hold | |
| 11/07/2023 | 551.63% | HC Wainwright & Co. | $20 → $13 | Maintains | Buy |
| 10/23/2023 | 250.88% | Barclays | $8 → $7 | Maintains | Overweight |
| 09/26/2023 | 902.51% | Truist Securities | → $20 | Reiterates | Buy → Buy |
| 09/26/2023 | 902.51% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 08/03/2023 | 902.51% | HC Wainwright & Co. | $24 → $20 | Maintains | Buy |
| 07/24/2023 | 501.5% | Citigroup | → $12 | Initiates Coverage On | → Buy |
| 07/14/2023 | 902.51% | Truist Securities | $22 → $20 | Maintains | Buy |
| 06/28/2023 | 1002.76% | Truist Securities | → $22 | Reiterates | Buy → Buy |
| 06/20/2023 | 1002.76% | Truist Securities | $24 → $22 | Maintains | Buy |
| 06/20/2023 | 1103.01% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 06/15/2023 | 1103.01% | Truist Securities | → $24 | Reiterates | Buy → Buy |
| 06/06/2023 | 1103.01% | HC Wainwright & Co. | → $24 | Reiterates | → Buy |
| 06/01/2023 | 1103.01% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 05/23/2023 | 301% | Barclays | $13 → $8 | Maintains | Overweight |
| 05/09/2023 | 1103.01% | HC Wainwright & Co. | $26 → $24 | Maintains | Buy |
| 05/01/2023 | 1103.01% | Truist Securities | → $24 | Initiates Coverage On | → Buy |
| 03/28/2023 | 451.38% | UBS | → $11 | Upgrades | Neutral → Buy |
| 03/08/2023 | 551.63% | Barclays | $15 → $13 | Maintains | Overweight |
| 03/07/2023 | 1203.26% | HC Wainwright & Co. | $30 → $26 | Maintains | Buy |
| 11/16/2022 | 952.63% | Mizuho | $28 → $21 | Maintains | Buy |
| 11/14/2022 | 451.38% | JP Morgan | $13 → $11 | Maintains | Neutral |
| 08/16/2022 | 1303.51% | Mizuho | $25 → $28 | Maintains | Buy |
| 06/14/2022 | 250.88% | UBS | → $7 | Initiates Coverage On | → Neutral |
| 05/20/2022 | 1153.13% | Mizuho | $30 → $25 | Maintains | Buy |
| 05/09/2022 | 651.88% | Barclays | $20 → $15 | Maintains | Overweight |
| 03/07/2022 | 651.88% | JP Morgan | → $15 | Downgrades | Overweight → Neutral |
| 11/09/2021 | 1403.76% | HC Wainwright & Co. | $36 → $30 | Maintains | Buy |
| 07/23/2021 | 1704.51% | HC Wainwright & Co. | $26 → $36 | Maintains | Buy |
| 05/17/2021 | 1103.01% | Barclays | $28 → $24 | Maintains | Overweight |
| 05/07/2021 | 1203.26% | HC Wainwright & Co. | $29 → $26 | Maintains | Buy |
| 02/25/2021 | 1353.63% | HC Wainwright & Co. | $33 → $29 | Maintains | Buy |
| 11/19/2020 | 1403.76% | Mizuho | $35 → $30 | Maintains | Buy |
| 11/06/2020 | 1504.01% | HC Wainwright & Co. | $33 → $32 | Maintains | Buy |
| 08/10/2020 | 1403.76% | Truist Securities | $26 → $30 | Maintains | Buy |
| 08/07/2020 | 1554.14% | HC Wainwright & Co. | $30 → $33 | Maintains | Buy |
| 07/16/2020 | 902.51% | B of A Securities | → $20 | Initiates Coverage On | → Neutral |
| 04/17/2020 | 1203.26% | SunTrust Robinson Humphrey | → $26 | Initiates Coverage On | → Buy |
| 02/28/2020 | 1403.76% | HC Wainwright & Co. | $29 → $30 | Reiterates | → Buy |
| 02/06/2020 | 1654.39% | JP Morgan | $33 → $35 | Maintains | Overweight |
| 11/07/2019 | 1453.88% | Citigroup | $27 → $31 | Maintains | Buy |
| 08/13/2019 | 2055.39% | Mizuho | → $43 | Initiates Coverage On | → Buy |
| 06/11/2019 | 1403.76% | Barclays | → $30 | Initiates Coverage On | → Overweight |
| 05/07/2019 | 1303.51% | HC Wainwright & Co. | → $28 | Initiates Coverage On | → Buy |
What is the target price for Coherus BioSciences (CHRS)?
The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Truist Securities on November 28, 2023. The analyst firm set a price target for $12.00 expecting CHRS to rise to within 12 months (a possible 501.50% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Coherus BioSciences (CHRS)?
The latest analyst rating for Coherus BioSciences (NASDAQ: CHRS) was provided by Truist Securities, and Coherus BioSciences reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Coherus BioSciences (CHRS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Coherus BioSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Coherus BioSciences was filed on November 28, 2023 so you should expect the next rating to be made available sometime around November 28, 2024.
Is the Analyst Rating Coherus BioSciences (CHRS) correct?
While ratings are subjective and will change, the latest Coherus BioSciences (CHRS) rating was a reiterated with a price target of $0.00 to $12.00. The current price Coherus BioSciences (CHRS) is trading at is $2.00, which is within the analyst's predicted range.
